Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Journal of Chemotherapy (Florence, Italy)|September 13, 2021
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patientsBahar Uncu Ulu, Mehmet Sinan Dal, İpek Yönal Hindilerden, et al.
Annals of Hematology|November 19, 2022
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from TurkeyMehmet Sinan Dal, Bahar Uncu Ulu, Ant Uzay, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|November 21, 2017
Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)Emre Tekgündüz, Fatih Demirkan, Filiz Vural, et al.
British Journal of Haematology|June 17, 2025
Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohortUmut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|October 22, 2019
Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B Instead of Hepatitis C Virus as an Etiologic and Possible Prognostic Factor - A Multicenter Cohort StudyMüfide Okay, Tuncay Aslan, Evren Özdemir, et al.
Leukemia & Lymphoma|September 13, 2024
A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patientsÖzgür Mehtap, Tayfur Toptas, Mehmet S Dal, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|November 7, 2025
A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting TherapiesUmut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, et al.
Cancer|December 30, 2025
Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patientsUmut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|November 6, 2024
Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter AnalysisÜnal Ataş, Ozan Salim, Utku Iltar, et al.
Pageof 9